WuXi PharmaTech (Cayman), Inc. (ADR) (NYSE:WX)

CAPS Rating: 4 out of 5

China-based pharmaceutical and biotechnology R&D outsourcing company which provides a integrated portfolio of laboratory and manufacturing services in the drug discovery and development process to pharmaceutical and biotechnology companies.

Results 1 - 20 of 37 : 1 2 Next »

Recs

0
Member Avatar cryptelligence (66.66) Submitted: 7/3/2014 6:53:07 PM : Outperform Start Price: $33.27 WX Score: +10.40

Algae play

Recs

0
Member Avatar timothy55 (< 20) Submitted: 2/11/2012 10:09:35 AM : Outperform Start Price: $13.84 WX Score: +119.85

Stock could be a buyout candidate. Company has been growing steady since its IPO and still hasn't surpassed the IPO price of $14 as of Feb 10. Stock should be in at least in the low $20 range

Recs

0
Member Avatar GUOCHONGHUA (56.47) Submitted: 7/7/2011 6:48:27 AM : Outperform Start Price: $16.79 WX Score: +72.76

Intrinsic:10.46

Recs

0
Member Avatar gwanoy (< 20) Submitted: 4/26/2010 10:06:55 PM : Outperform Start Price: $19.15 WX Score: +27.91

high quality, inexpensive pharmaceutical R&D.

Recs

0
Member Avatar jmt587 (99.88) Submitted: 9/28/2009 3:00:37 PM : Outperform Start Price: $12.00 WX Score: +120.41

Chinese BioTech & Pharma Outsourcing company.

Recs

0
Member Avatar oxdeming (59.77) Submitted: 9/11/2009 4:38:13 AM : Outperform Start Price: $11.55 WX Score: +129.37

China pharm is in the rising

Recs

0
Member Avatar pslorenz (95.27) Submitted: 4/6/2009 1:00:32 PM : Outperform Start Price: $4.95 WX Score: +503.19

Outsourcing is and will continue to be a hot ticket item. Outsourcing pharma R&D is an interesting concept.

Recs

0
Member Avatar michaellee1818 (< 20) Submitted: 3/2/2009 10:28:01 AM : Underperform Start Price: $4.21 WX Score: -597.48

fxp

Recs

0
Member Avatar ironyworks (68.32) Submitted: 1/1/2009 2:17:22 AM : Outperform Start Price: $8.00 WX Score: +237.87

Chinese medical services

Recs

2
Member Avatar tskephart (81.56) Submitted: 11/26/2008 12:30:32 PM : Outperform Start Price: $5.97 WX Score: +383.63

Pharmaceutical R&D is a very expensive part of the pharmaceutical market. I feel their will be a paradigm shift on how global pharmaceutical companies approach research, one of the results will be more outsourcing and collaborations.. WuXi is positioned well to take advantage of this shift.

Recs

0
Member Avatar lwc123 (41.93) Submitted: 10/23/2008 12:39:55 PM : Outperform Start Price: $7.07 WX Score: +293.10

8x trailing EBITDA. 75% earnings growth. Market leader in China. Outsourcing is a natural in down markets. The pharma customer base is steady in a down market. Good risk-reward.

Recs

0
Member Avatar deafdumbnblind (< 20) Submitted: 10/22/2008 7:23:07 PM : Outperform Start Price: $7.50 WX Score: +266.94

excellent company, great growth....PE 6.21 get some balls and buy !

Recs

0
Member Avatar EagleTraderOne (< 20) Submitted: 9/10/2008 5:04:13 PM : Underperform Start Price: $15.77 WX Score: -66.06

Still a way to go...down. Not a buy...yet.

Recs

0
Member Avatar crimfunk (75.14) Submitted: 6/16/2008 4:48:06 PM : Outperform Start Price: $17.99 WX Score: +54.58

supercycle

Recs

0
Member Avatar j1e1k1 (94.86) Submitted: 6/7/2008 9:57:13 AM : Outperform Start Price: $19.69 WX Score: +37.00

No-brainer.

Booming industry in booming country at a great price!

Recs

0
Member Avatar stockgaucho (< 20) Submitted: 5/27/2008 11:44:04 PM : Outperform Start Price: $22.23 WX Score: +17.66

For some reason I foresee this first quarter doubled profit company performing well in the future.

Recs

0
Member Avatar deuspecuniae (96.56) Submitted: 5/1/2008 12:11:17 PM : Outperform Start Price: $17.77 WX Score: +60.02

The looming recession that bernanke and the whole federal reserve gang have set this country towards will send alot of investors into the pharmaceutical's sector--being the traditional recessionary savior to say the least. Plus, most pharmaceutical stocks have been beaten down this past winter, and I see a reversal across the entire sector. Also, those companies already on a run will continue due to the upward momentum this summer from key reversals and upgrades throughout the sector.

Recs

0
Member Avatar EJDoran (81.03) Submitted: 3/28/2008 1:56:17 PM : Outperform Start Price: $22.30 WX Score: +9.35

While the Chinese market is open, someone has to be the top dog in the Chinese pharma market and my bet is on these guys. Well run, low costs in a usually high cost sector, huge and growing market.

Recs

0
Member Avatar FLORIDAMONEYMAN (< 20) Submitted: 3/13/2008 10:14:26 PM : Outperform Start Price: $22.13 WX Score: +10.67

FDA gave some good coments with this one, fast short run for a blast cash grab.

Recs

0
Member Avatar acbinvestor (< 20) Submitted: 1/10/2008 11:22:02 PM : Outperform Start Price: $28.54 WX Score: -17.95

US economic recession is on the horizon.

Big pharmas have to cut costs and downsize. But R&D can not slow down. Thus, outsourcing is the trend. They can outsource to US based companies or overseas companies. WX has a huge cost advantage.

With the recent Apptec acquisition, it expands its service range and customer base. BTW, the IPO cash it harvested hasn't been touched since it maintains cash positive flow for years now. To make the money to work by buying Apptec is a smart move.

WX is the best drug research companies in China. With its huge talent pool and the enormous market potential in China, sky is the limit.

By setting up the first life science award in China, WX solidified its leadership status in China. The move enables WX to establish close ties to Chinese officials, academic researchers, potential talent pool and other industry insiders. With a small amount of money to hand out, it achieved the greatest PR result. Smart management team.

If you hear CVD's CEO saying that they have more outsource jobs than they can handle, you know WX will not be short of jobs.

Results 1 - 20 of 37 : 1 2 Next »

Featured Broker Partners


Advertisement